Beyond Thinking
Welcome to Beyond Blue’s Thought Leadership Hub, where we highlight complex concepts with clarity and showcase our commitment to delivering excellence with ease. Explore our insights, discover innovative perspectives and join us on a journey to navigate the intricate with confidence.
The BTKi rollercoaster in MS continues to surprise
Author: Nikita Shah, Beyond Neurology The rollercoaster in the MS fairground has taken another sharp turn. Tolebrutinib has missed its primary endpoint in the Phase 3 PERSEUS trial in PPMS, and the already delayed FDA decision for its nrSPMS indication now looks...
Using behavior change models to ensure a more holistic assessment of health conditions
Behavior Change models condense many years of research on the influences shaping our actions. In healthcare market research, there continues to be significant focus on COM-B, given its wide applicability. We should not, however, overlook the potential contribution of...
Multiple Myeloma at ASH 2025: Navigating a rapidly evolving landscape
The multiple myeloma (MM) landscape continues to evolve at a rapid pace. Key data presented at ASH spanned CAR-T therapies (long-term data from CARTITUDE-4, iMMagine-1), bispecific antibodies (MAJESTEC-3), antibody–drug conjugates (long-term data from DREAMM-7 &...
Cut the Clutter: How quantitative testing drives message precision
Too many messages, too little time. Brand teams often face a conveyor belt of messages and visuals, each one rolling past with its own merit, creative direction, and strategic grounding. But HCPs are time-poor, and in both testing and real-life sales, we have only...
Celebrating Culture and Connection: Manchester meetup
Author: Kelly Shipley, Head of Talent On 1st October, we did something special. We brought our global team together in person for the start of our annual networking and connection day. We met at our city centre venue in Manchester to connect, share, and identify...
ESMO 2025 Reflections
Four potentially practice-changing bladder cancer papers This year’s ESMO congress delivered a wealth of impactful data across the bladder cancer spectrum, from muscle-invasive to metastatic disease. Here are four standout studies with potential to reshape clinical...
When the Gates Stay Closed: Strategic guidance on what to do when launch delays hit
Author: Alex Hunt, Research Manager, Beyond Blue Strategy In the recent article from our Beyond Neurology team, we traced the journey of BTK inhibitors (BTKi) in Multiple Sclerosis (MS), a story marked by scientific promise, high expectations, and a few sharp turns...
CoLoop vs Professional Translation: A pragmatic comparison for researchers
Author: Mike Pepp, Senior Commercial Consultant, Beyond Blue Like many agencies, we are always striving to use new technologies that reduce time to insight – balancing this with the need to have confidence that the quality of our learnings and insights is maintained...
ESMO 2025: Ones to watch
Explore the headlines set to surface at ESMO 2025. ADCs make their move into early-stage disease Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and...
